The use of an LH-RH agonist (ICI 118630, Zoladex) in advanced premenopausal breast cancer.

Fifty-three premenopausal patients presenting with advanced breast cancer have been treated with a potent new luteinising hormone-releasing hormone agonist Zoladex (ICI 118630) in a phase I clinical trial. On progression of disease 26 patients have undergone therapeutic oophorectomy. We present the...

Descripción completa

Detalles Bibliográficos
Autores principales: Williams, M. R., Walker, K. J., Turkes, A., Blamey, R. W., Nicholson, R. I.
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 1986
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2001373/
https://www.ncbi.nlm.nih.gov/pubmed/2941044
_version_ 1782135591658323968
author Williams, M. R.
Walker, K. J.
Turkes, A.
Blamey, R. W.
Nicholson, R. I.
author_facet Williams, M. R.
Walker, K. J.
Turkes, A.
Blamey, R. W.
Nicholson, R. I.
author_sort Williams, M. R.
collection PubMed
description Fifty-three premenopausal patients presenting with advanced breast cancer have been treated with a potent new luteinising hormone-releasing hormone agonist Zoladex (ICI 118630) in a phase I clinical trial. On progression of disease 26 patients have undergone therapeutic oophorectomy. We present the clinical and endocrinological responses to treatment in 45 assessable patients. The response rate to Zoladex in this series was 31% and the ER status of the primary tumour was predictive of a response to the luteinising hormone-releasing hormone.
format Text
id pubmed-2001373
institution National Center for Biotechnology Information
language English
publishDate 1986
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-20013732009-09-10 The use of an LH-RH agonist (ICI 118630, Zoladex) in advanced premenopausal breast cancer. Williams, M. R. Walker, K. J. Turkes, A. Blamey, R. W. Nicholson, R. I. Br J Cancer Research Article Fifty-three premenopausal patients presenting with advanced breast cancer have been treated with a potent new luteinising hormone-releasing hormone agonist Zoladex (ICI 118630) in a phase I clinical trial. On progression of disease 26 patients have undergone therapeutic oophorectomy. We present the clinical and endocrinological responses to treatment in 45 assessable patients. The response rate to Zoladex in this series was 31% and the ER status of the primary tumour was predictive of a response to the luteinising hormone-releasing hormone. Nature Publishing Group 1986-05 /pmc/articles/PMC2001373/ /pubmed/2941044 Text en https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.
spellingShingle Research Article
Williams, M. R.
Walker, K. J.
Turkes, A.
Blamey, R. W.
Nicholson, R. I.
The use of an LH-RH agonist (ICI 118630, Zoladex) in advanced premenopausal breast cancer.
title The use of an LH-RH agonist (ICI 118630, Zoladex) in advanced premenopausal breast cancer.
title_full The use of an LH-RH agonist (ICI 118630, Zoladex) in advanced premenopausal breast cancer.
title_fullStr The use of an LH-RH agonist (ICI 118630, Zoladex) in advanced premenopausal breast cancer.
title_full_unstemmed The use of an LH-RH agonist (ICI 118630, Zoladex) in advanced premenopausal breast cancer.
title_short The use of an LH-RH agonist (ICI 118630, Zoladex) in advanced premenopausal breast cancer.
title_sort use of an lh-rh agonist (ici 118630, zoladex) in advanced premenopausal breast cancer.
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2001373/
https://www.ncbi.nlm.nih.gov/pubmed/2941044
work_keys_str_mv AT williamsmr theuseofanlhrhagonistici118630zoladexinadvancedpremenopausalbreastcancer
AT walkerkj theuseofanlhrhagonistici118630zoladexinadvancedpremenopausalbreastcancer
AT turkesa theuseofanlhrhagonistici118630zoladexinadvancedpremenopausalbreastcancer
AT blameyrw theuseofanlhrhagonistici118630zoladexinadvancedpremenopausalbreastcancer
AT nicholsonri theuseofanlhrhagonistici118630zoladexinadvancedpremenopausalbreastcancer
AT williamsmr useofanlhrhagonistici118630zoladexinadvancedpremenopausalbreastcancer
AT walkerkj useofanlhrhagonistici118630zoladexinadvancedpremenopausalbreastcancer
AT turkesa useofanlhrhagonistici118630zoladexinadvancedpremenopausalbreastcancer
AT blameyrw useofanlhrhagonistici118630zoladexinadvancedpremenopausalbreastcancer
AT nicholsonri useofanlhrhagonistici118630zoladexinadvancedpremenopausalbreastcancer

Ejemplares similares